Printer Friendly

Quality concerns uncovered at laboratories doing waived tests.

A national survey has found that serious problems exist in the quality of work performed by laboratories doing certificate of waiver tests and provider-performed microscopy procedures.

Serious problems exist in the quality of work performed by laboratories doing certificate of waiver tests (COW) and provider-performed microscopy procedures (PPMP), according to results from a recent national survey by the Centers for Medicare Services (CMS), formerly known as the Health Care Financing Administration (HCFA).

Laboratory tests that receive a waiver from CLIA (Clinical Laboratory Improvement Amendments of 1988) are the least regulated tests, with no routine oversight under that federal law.

CLIA regulations define waived tests as simple laboratory examinations and procedures that are cleared by the federal government for home use; that employ methodologies that are so simple and accurate that erroneous results would be negligible; or that pose no reasonable risk of harm to the patient if the test is performed incorrectly.

CLIA lists a number of lab tests that receive waivers, including fecal occult blood tests, ovulation tests, urine pregnancy tests, and dipstick or tablet reagent urinalysis for biliru-bin, glucose, hemoglobin, protein, and nitrite.

Approximately 52 percent of the nation's laboratories perform only waived tests, and 22 percent are limited to performing waived and/or microscopy tests. As a result, more than 74 percent of the nation's laboratories fall outside the purview of routine government oversight, according to CMS. The remaining laboratories, which perform moderate and/or high complexity laboratories tests, must follow specific requirements for quality control and assurance, personnel qualifications, proficiency testing, and routine biennial inspections.

As more tests are classified as waived, some in the laboratory industry say the definition of waived tests may require review. "When waived testing was established, it was designed for procedures that were simple to perform and didn't have any mechanical element. Now what we have in many of these (waived) applications is a kit or box that is simple to operate, but is complicated internally and accomplishes very sophisticated testing," says Mark Birenbaum, PhD, administrator for the American Association of Bioanalysts (AAB), a national professional association whose members are directors, owners, managers, and supervisors of community clinical laboratories.

To perform waived tests, laboratories must enroll in the CLIA program, become certified, pay a certificate fee, and follow the manufacturer's instructions for each waived test. Many of the laboratories performing waived tests are located in physicians' offices.

Because of the quality problems recently documented by the CMS survey, such as waived labs not performing quality control as required by the manufacturer, industry leaders worry that inaccurate testing will proliferate, causing harm to patients. The survey did not have outcome data to show adverse effects on patient care.

Carolyn Jones, vice present for technology and regulatory affairs for the Advanced Medical Technology Association (AdvaMed) says these concerns are "inappropriate." AdvaMed represents more than 1,000 manufacturers of medical devices, diagnostic products and medical information systems. Further, she says, "a product that is waived has gone through an approval process. The waiver is an additional review to look at the simplicity of the instructions to determine if an untrained user can obtain the same results as a trained user."

Waived tests also have an impact on the laboratories that must comply with CLIA regulations. "Waived laboratories don't have to hire trained personnel, do proficiency testing, or comply with CLIA recordkeeping and quality control requirements, which gives them an economic advantage over a regulated lab," Birenbaum says.

To address the quality problems uncovered in waived laboratories, CMS is taking steps to assure that improvements are made.

CMS survey uncovers quality problems

When CMS surveyed 270 COW laboratories and 190 PPMP laboratories between October 2000 and January of this year, it found 48 percent of waived and 38 percent of PPMP labs were experiencing quality testing problems.

In the COW labs, CMS found a number of problems, including practices such as failing to follow manufacturer's instructions, using expired reagents, and testing beyond the scope of the complexity level for which the lab was certified. With PPMP labs, the deficiencies ranged from not evaluating test accuracy to problems with microscope/centrifuge maintenance.

CMS is not alone in its findings. The Department of Health and Human Services Office of Inspector General (OIG) completed a similar survey of waived laboratories and uncovered deficiencies in both types of labs. Some of the problems the OIG found included misunderstanding of CLIA requirements, untrained staff, and failure to identify incorrect results.

When asked about the results of the survey, Paul Fischer, MD, a primary care physician in Augusta, GA, says that "most of what has been approved for waived testing is perfectly appropriate, and the problems the survey found were not things that are likely to lead to patient care problems." Fischer is a consultant for the American Academy of Family Physicians on laboratory issues and proficiency testing.

Education is key to improvement

As a result of the deficiencies uncovered, CMS is calling on waived and PPMP laboratories to take a number of corrective steps.

The primary focus of the agency's recommendations is education, says Judith Yost, the CMS official who oversees CLIA for the agency. "Education is the most important and the first thing we will work on," she adds. The aim of such efforts is to help those in the lab to better understand how to perform the tests properly.

Because those performing waived tests often don't understand the labeling instructions, CMS also plans to work with professional associations, such as AdvaMed, to help spearhead education efforts for waived lab personnel. "We need to clarify the language as well as the instructions," Yost says.

Jones says AdvaMed strongly supports better education to improve the quality of work waived labs perform. Manufacturers would Be "prepared to help with such an effort," she adds.

Jones also points out that the difficulties in dealing with small labs is that they are somewhat disconnected from the rest of the lab community. It would help, she believes, if the rest of the lab community finds some way to make small labs more connected so the same type of information distributed to traditional clinical labs can find their way to waived labs.

The difficulties in dealing with small labs is that they are somewhat disconnected from the rest of the lab community.

In addition to education, CMS is considering the development of a self-assessment tool for PPMP labs. Yost says the agency may continue to periodically survey both types of labs to make sure the recent problems are being addressed by lab personnel as well as physicians and nurses who are ultimately responsible for the work being performed.

The OIG issued a set of recommendations to address quality problems it found. It suggested that routine inspections of moderate/high complexity labs include a review of any waived/PPMP testing performed.

"Even though all the corrective steps that have been proposed would be beneficial, they are not really addressing the core of the problem," says AAB's Birenbaum. "The major problem centers on the definition of waived tests, which has been expanded beyond what Congress originally intended."

FDA's role

While CMS works on finding a way to educate waived labs on how to improve the quality of the work performed, some in the lab industry are concerned about the expanded role the Food and Drug Administration (FDA) now has with regard to waived testing.

Over the past year, FDA has been granting premarket approval for many new diagnostic kits that are coming to market. In addition, when the FDA approves a test for home and over-the-counter use, that test also wins approval under law for a CLIA waiver.

The FDA has responsibility to categorize lab tests, determining whether they should be considered waived, moderate, or high complexity. This was formerly accomplished by the Centers for Disease Control and Prevention (CDC). In 1999, an interagency agreement transferred the responsibility for this job from CDC to FDA.

In this role, the FDA recently asked for comments on draft guidance it proposed to medical device manufacturers and others on an alternative method to obtain CLIA waived status for products. Critics claim the FDA proposal will result in the agency being less restrictive on granting waivers than was the CDC.

Responding to the FDA request for comments, AAB said it believes "all tests granted CLIA waiver should be held to the same stringent standards for accuracy and precision and meet the same requirements for design, labeling, quality control, and training and monitoring of field users."

AAB's Birenbaum says that once a manufacturer gets a home test kit or product into the waived category, it has a big marketing advantage. He explained that once in the waived category, the test can be sold to physician laboratories.

The Clinical Laboratory Improvement Advisory Committee has expressed its concern over the FDA's decision to automatically waive home-use tests. The panel is concerned that home use approval will become a "back door" method for winning CLIA waiver approval. It pointed out that the criteria used for home-use tests are not equal to other waiver approval criteria.

As manufacturers and physicians push to win approval for more waivers, some in the lab field worry that the industry is headed toward deregulation. "If the government keeps expanding the category of waived testing, soon the federal rules won't apply to anything," Birenbaum says. Organized medicine, he says, has been trying to repeal CLIA for some time. "They were unsuccessful, and they see this (waiver route) as another way to achieve the same objective," he says.

In addition, he points out that manufacturers are following "the route of least resistance. If it is much simpler to get a test approved via the home test kit, then they will take that route.

While AdvaMed understands these concerns, Jones says the lab industry is "going to have to come to grips with the fact that traditional clinical labs may not stand the test of time."

In the meantime, CMS' Yost says the agency will continue to monitor waived labs and pursue efforts to bring about better management of the program.

Joan Szabo, a Washington-based freelance writer, is the author of "Washington Report," a monthly column in MLO.
Recent waived tests

Following is a list of some of the
tests that have recently received a
CLIA waiver from the Food and Drug
Administration:


Test System Name Decision Date

Orasure Technologies QED Saliva January 22, 2001
 Alcohol Test
Home Diagnostic Genicare Blood February 26, 2001
 Glucose System
Home Diagnostics Prestige IQ Blood March 26, 2001
 Glucose System
Cholestech LDX April 13, 2001
Bayer Multistix Pro 11 Reagent May 1, 2001
 Strips
Beckman Coulter Icon DS HCG Test April 23, 2001
 Strip (Urine)
Genzyme Signify HCG Urine Serum May 2, 2001
 Test



Source: U.S. Food and Drug
Administration


What the CMS survey found

In its national survey, the Centers for Medicare and Medicaid Services (CMS) found the following types of quality problems existed in labs performing certificate of waiver tests:

32 percent failed to include current manufacturer's instructions

32 percent didn't perform quality control as required by the manufacturer or CDC

20 percent cut occult blood cards and urine dipsticks

19 percent of the labs personnel were neither trained nor evaluated

16 percent failed to follow current manufacturer's instructions

9 percent were not following manufacturer's storage and handling instructions

7 percent didn't perform calibration as required by manufacturer

Source: Center for Medicare and Medicaid Services
COPYRIGHT 2001 Nelson Publishing
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Author:Szabo, Joan
Publication:Medical Laboratory Observer
Article Type:Statistical Data Included
Date:Oct 1, 2001
Words:1901
Previous Article:Complications of critical care: Lab testing and iatrogenic anemia.
Next Article:Memory monitoring thermometers.
Topics:


Related Articles
Pharmacies move in on labs.
CLIAC meeting recap.
News from the Latest CLIAC Meeting.
FDA offers CLIA test categorization database, CMS plans inspections in waived and PPMP laboratories, and ICD.9 coding is clarified. (POL adviser).
HHS designates CMS as lead agency on CLIA waivers. (Washington report).
What do you want from your reference laboratory? A report card on send-out testing in the Pacific Northwest.
CMS launches survey of certificate of waiver laboratories. (Washington Report).
News from the latest CLIAC meeting. (POL Adviser).
Waiver criteria engenders lively discussion.
A sixth-grader can do it.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters